Sweet Bee Venom Pharmacopuncture for Chemotherapy-Induced Peripheral Neuropathy

Yoon, Jeungwon; Jeon, Ju-Hyun; Lee, Yeon‐Weol; Cho, Chong-Kwan; Kwon, Ki-Rok; Shin, Jumi A.; Sagar, Stephen M.; Wong, Raimond; Yoo, Hwa‐Seung

doi:10.1016/j.jams.2012.05.003

Cited by 37 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other herbal medicines which showed promise as protective agents include Kieshikajutsubuto[124] and Shakuyaku-Kanzo-to[126] while sweet bee venom may be useful in treating CIPN once it has developed. [130131]…”

Section: Resultsmentioning

confidence: 99%

New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

Schloss

Colosimo

Vitetta

2016

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Objective:Neurological complications such as chemotherapy-induced peripheral neuropathy (CIPN) and neuropathic pain are frequent side effects of neurotoxic chemotherapy agents. An increasing survival rate and frequent administration of adjuvant chemotherapy treatments involving neurotoxic agents makes it imperative that accurate diagnosis, prevention, and treatment of these neurological complications be implemented.Methods:A consideration was undertaken of the current options regarding protective and treatment interventions for patients undergoing chemotherapy with neurotoxic chemotherapy agent or experience with CIPN. Current knowledge on the mechanism of action has also been identified. The following databases PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, CINAHL, CNKI, and Google Scholar were searched for relevant article retrieval.Results:A range of pharmaceutical, nutraceutical, and herbal medicine treatments were identified that either showed efficacy or had some evidence of efficacy. Duloxetine was the most effective pharmaceutical agent for the treatment of CIPN. Vitamin E demonstrated potential for the prevention of cisplatin-IPN. Intravenous glutathione for oxaliplatin, Vitamin B6 for both oxaliplatin and cisplatin, and omega 3 fatty acids for paclitaxel have shown protection for CIPN. Acetyl-L-carnitine may provide some relief as a treatment option. Acupuncture may be of benefit for some patients and Gosha-jinki-gan may be of benefit for protection from adverse effects of oxaliplatin induced peripheral neuropathy.Conclusions:Clinicians and researchers acknowledge that there are numerous challenges involved in understanding, preventing, and treating peripheral neuropathy caused by chemotherapeutic agents. New insights into mechanisms of action from chemotherapy agents may facilitate the development of novel preventative and treatment options, thereby enabling medical staff to better support patients by reducing this debilitating side effect.

show abstract

Section: Resultsmentioning

confidence: 99%

New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

Schloss

Colosimo

Vitetta

2016

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

show abstract

“…Treatments such as Acupuncture [80][81][82]; Sweet bee venom pharmacopuncture [83,84]; Kampo diagnosis and therapy [85] were documented in the literature. and included treatments such as TENS, hot/cold application, flexibility and strengthening exercises, and manual physical therapy methods such as nerve massage and nerve slider techniques (for those who present with positive nerve palpation and neurodynamic tests).…”

Section: Alternative Therapiesmentioning

confidence: 99%

Assessment and Treatment of Chemotherapy-induced Peripheral Neuropathy- a Physical Therapy Perspective

Kumar

Jamwal

2015

GJCT

View full text Add to dashboard Cite

Chemotherapy is recognized as a mainline treatment for all types of cancer, and its most debilitating and dose-limiting complication is Chemotherapy-induced peripheral neuropathy (CIPN), the mechanisms of nerve damage of which depends upon the specific chemotherapeutic agent used. Use of non-invasive treatment methods such as physical therapy may provide a valuable therapeutic adjunctive option in patients with CIPN. Physical therapy treatment methods had been shown to produce effective symptom control and enhance quality of life in palliative care. A detailed evidence-based update of literature is provided under evaluation and management of CIPN with a special perspective of physical therapy management using a proposed clinical reasoning-based treatment decision making algorithm so that an Ã¢â‚¬Ëœout of the boxÃ¢â‚¬â„¢ self-reflective evidence-informed critical thinking process is applied along a collaborative multidisciplinary biopsychosocial approach.Ã‚Â Keywords: Chemotherapy-induced neurotoxicity; Chemotherapy-induced neuropathy; Physical therapy; Palliative rehabilitation

show abstract

“…Therefore, intensive studies are currently underway to prevent and alleviate CIPN symptoms [15][16][17][18][19], and attempts are being made to standardize CIPN assessments [20]. Nevertheless, there are a limited number of studies concerning the QOL of cancer patients who experience CIPN-related symptoms [11,20,21], and studies on the CIPN-QOL relationship in patients with hematologic malignancies are rare.…”

Section: Introductionmentioning

confidence: 99%

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Song

Kim

Lee

2015

Korean J Adult Nurs

View full text Add to dashboard Cite

Purpose: This study was aimed to identify the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) among patients with hematologic malignancies and to examine the relationship between the quality of life (QOL) and CIPN. Methods: A total of 66 patients with CIPN-related symptoms participated in this study. Data were collected through self-reported questionnaires consisted of the European Organization for Research and Treatment of Cancer QLQ-C30 version 3.0 and the 16-item QLQ-CIPN20. Data were analyzed with SPSS/ WIN20 for descriptive statistics using the Mann-Whitney and Kruskal-Wallis tests, and Spearman's rho. Results: The mean lower and upper extremity scale scores were 31.95 and 23.16 respectively for the 16-item QLQ-CIPN20. The mean QLQ-C30 subcategory scores were 46.84 for global health status, 58.72 for functional scales, and 34.85 for symptom scales. The CIPN-related lower extremity scale symptoms correlated negatively with the QOL subscales. There was no correlation between CIPN-related upper extremity symptoms and health-related QOL. Conclusion: Patients with hematologic malignancies treated with neurotoxic chemotherapeutic agents had CIPN-related symptoms in the lower extremities mainly, and their QOL functional subscale scores were relatively lower than those of other cancer patients. Interventions need to be developed for patients with hematologic malignancies to alleviate CIPN and enhance their QOL.

show abstract

Sweet Bee Venom Pharmacopuncture for Chemotherapy-Induced Peripheral Neuropathy

Abstract: The positive result of the study supports the potential value of conducting a fully powered trial to explore further efficacy of SBVP for CIPN. However a single positive result within this pilot study must be interpreted with caution.

Cited by 37 publications

References 38 publications

New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy

Assessment and Treatment of Chemotherapy-induced Peripheral Neuropathy- a Physical Therapy Perspective

Relationship between Chemotherapy-induced Peripheral Neuropathy and Quality of Life in Patients with Hematologic Malignancies

Contact Info

Product

Resources

About